Tesamorelin

Researchers use tesamorelin to investigate GRF/GHRH-receptor signaling on pituitary somatotrophs, downstream GH and IGF-1 release, and related body-composition endpoints such as visceral adipose tissue. Published trials of the prescription formulation provide a benchmark evidence base that lab investigators reference. All applications here are laboratory-based, RUO only.

Tesamorelin and Sermorelin are both analogs of growth hormone-releasing factor (GHRH), though Sermorelin uses only the shorter 1-29 fragment and was discontinued from the US prescription market by its manufacturer in 2008, with FDA formally withdrawing its approval in 2009 for business, not safety, reasons. Ipamorelin instead acts through the separate ghrelin/GHRP receptor pathway. None of the three should be treated as interchangeable, and no human trial establishes a combination protocol for any pairing of them.

A complete COA includes HPLC purity, an identity confirmation, physical appearance, and a lot number. On receipt, match the lot number on the document to the one on the vial. A mismatch means the COA does not cover the material you received.

It means 99% or more of the material, by HPLC analysis, is intact tesamorelin rather than fragments or impurities. Purity does not establish sterility, biological activity, or suitability for any human use. Those conclusions require separate testing.

Follow the label and COA for this specific lot. Lyophilized peptides are generally stored cold and protected from light; reconstituted material is generally refrigerated and used within a defined window. Specific conditions and timelines depend on your protocol and the lot's own documentation.

No. This is a research chemical in the RUO category, legally distinct from the FDA-approved prescription drug Egrifta WR, which is indicated only for reducing excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for general weight-loss management. Researchers are responsible for confirming compliance with their own applicable regulations. This is not legal advice.

Available sizes are 10 and 20 mg. The right quantity depends entirely on the protocol's scale and the number of experimental runs planned. That determination belongs to the researcher, not the supplier.

The independent lab has no financial stake in the outcome. An in-house figure comes from the same organization selling the material, which creates a conflict of interest even when the testing is accurate. A third-party certificate gives the researcher an outside check on what they are buying.